Eli Lilly’s tirzepatide achieves 15.7% weight loss in adult patients

News

Eli Lilly has announced that tirzepatide (10mg and 15mg) achieved significant and superior weight loss compared to a placebo over 72 weeks of treatment. This data follows results from the SURMOUNT-2 trial, which met all co-primary and secondary endpoints.

The results showed that those taking tirzepatide lost up to 15.7% (34.4lb or 15.6kg) of body weight for the efficacy estimand. On a 10mg dose patients lost an average 13.4%, while 15mg dose patients demonstrated a loss of 15.7%.

Furthermore, 81.6% (10mg) and 86.4% (15mg) of patients taking the drug experienced at least 5% body weight reduction, which was the trial’s other co-primary endpoint, compared to only 30.5% of the placebo group.

The drug also met all secondary endpoints in the trial and the safety profile remained consistent to previously reported SURMOUNT and SURPASS trials. These secondary endpoints included reduction in A1C and other cardiometabolic parameters; 41.4% (10mg) and 51.8% (15mg) of patients taking the drug achieved at least 15% body weight reduction compared to only 2.6% of those in the placebo group.

Jeff Emmick MD PhD, senior vice president of product development at Eli Lilly, commented: “Obesity is a difficult-to-manage disease, and it’s even more difficult for people living with type 2 diabetes. The degree of mean weight reduction seen in SURMOUNT-2 has not been previously achieved in phase 3 trials for obesity or overweight and type 2 diabetes.”

AstraZeneca and Ionis share positive results from phase 3 trial for eplontersen

AstraZeneca and Ionis have announced positive results from their phase 3 neuro-ttransform trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (attrv-pn), showing that the companies’ drug eplontersen met all primary and secondary endpoints at 66 weeks compared to an external placebo group.

AbbVie shares results from phase 3 trial for atogepant migraine treatment

AbbVie has shared positive results from its phase 3 elevate study, which assessed atogepant for the preventative treatment of episodic migraines in patients who have previously had two to four unsuccessful classes of oral preventive medications.

Eli Lilly shares positive results from phase 3 study of donanemab for early Alzheimer’s disease

Eli Lilly has announced positive results from the trailblazer-alz 2 phase 3 trial assessing donanemab’s ability to slow cognitive and functional decline in people with early symptomatic Alzheimer’s disease.

GSK announces positive data from phase 3 trial for new UTI antibiotic

GSK has shared positive data from its phase 3 trial for gepotidacin as a new oral antibiotic for the treatment of uncomplicated urinary tract infections (uUTIs) in female adults and adolescents.

Vicore announces initiation of proof-of-concept study for endothelial dysfunction treatments

Vicore Pharma Holding AB has announced that it has dosed the first patient with C21 in its randomised, double-blind, placebo-controlled, cross-over clinical study of endothelial dysfunction.

AstraZeneca and Ionis share positive results from phase 3 trial for eplontersen

AbbVie shares results from phase 3 trial for atogepant migraine treatment

Eli Lilly shares positive results from phase 3 study of donanemab for early Alzheimer’s disease

GSK announces positive data from phase 3 trial for new UTI antibiotic

Vicore announces initiation of proof-of-concept study for endothelial dysfunction treatments

Pharmafocus

Categories

Social Footprints